Celldex Completes Enrollment In Global Phase 3 Program Of Barzolvolimab In Chronic Spontaneous Urticaria, Which Consists Of Two Phase 3 Trials, EMBARQ-CSU1 And EMBARQ-CSU2
Benzinga Newsdesk 8 months ago
News
Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) --
- Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU
- Topline data expected Q4 2026
- BLA submission planned for 2027
HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company's global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program conducted in antihistamine refractory CSU, including patients with advanced therapy experienced/refractory CSU. The studies included 43 countries and over 500 sites.